Home >> Company >> News

Bell Biosystems Closes Significant Convertible Debt Funding
The Company announced on May 1, 2018 that it has secured additional convertible debt financing from Tamiami Angel Fund III, LLC, a Naples Florida based professionally managed large angel fund.  This convertible debt note, which in combination with it’s other lead investor’s participation included Lite-Cap Partners, Caesar
Bell Biosystems, Inc. Announces Pre-Clinical Results of Major in Vivo Safety Study Milestone
PRESS RELEASE JAN 8, 2018 12:00 PST BERKELEY, Calif., January 8, 2018 (Newswire.com) - Bell Biosystems, Inc. (Bell) today presented the results of their latest pre-clinical safety study at the Biotech Showcase in San Francisco that runs concurrently with the annual J.P. Morgan Healthcare Conference. The study was designed in accordance
Bell Biosystems, Inc. to Present at the Biotech Showcase™ Annual Conference on January 8, 2018
BERKELEY, Calif. /January 3, 2018 – Bell Biosystems, Inc. today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 during the most important global annual healthcare meeting where commercial entities and the financial community come together to explore potential business opportunities at th
Ken Harris joins Bell Biosystems as the President & CEO
Bell Biosystems, a privately-held cell therapy biotools company focused on commercializing its Magnelle(R) cell labeling and tracking platform,  announced today that the Board has appointed Ken Harris as the new President and Chief Executive Officer, and Caleb Bell, Ph.D. the co-Founder and previous CEO will assume full tim
Winnie Wan joins Bell Biosystems Board of Directors
Bell Biosystems welcomes Winnie Wan to its Board of directors. Winnie Wan, Ph.D. is an industry veteran, with extensive experience in launching and building diagnostic and therapeutic businesses with start-ups and within large corporations in the last 30 years. She has successfully commercialized disruptive technologies from inception. Th
Bell Biosystems Announces Completion of a Significant Safety and Toxicology Milestone
In advance of the 35th annual JP Morgan Healthcare Conference hosted in San Francisco from January 9th through the 13th 2017, FierceBiotech covers Bell Biosystems recent completion of a signfiicant safety and toxicology study of a Magnelle-PoweredTM Cell Therapy. The full article can be read here: http://www.fiercebiotech.com/sponsored/be
Bell Biosystems receives $1.5M NIH Phase II SBIR award and is targeting neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) for clinical development of Magnelle® cell tracking.
San Francisco, CA – September 7, 2016 – Bell Biosystems, Inc., a biotechnology company focused on commercial advancement of cell therapies, announced today that it has been awarded a $1.5M Phase II SBIR grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), a division of the National Institutes of
Bell Biosystems announces publication in Nature Scientific Reports describing the use of Magnelle® cell tracking technology platform in cardiovascular cell therapy applications
San Francisco, CA – Bell Biosystems, Inc., a biotechnology company focused on developing in vivo cell tracking solutions for cell therapies, announced today the publication of a study in Nature Scientific Reports, describing how their Magnelle® cell tracking technology enables in vivo tracking of iPSC-derived cardiomyocytes for
Contact Us Sitemap Terms of Use
Follow Bell Biosystems
© 2018 Bell Biosystems. All rights are reserved
Website Security Test